Related references
Note: Only part of the references are listed.Evidence of distinct α-synuclein strains underlying disease heterogeneity
Sara A. M. Holec et al.
ACTA NEUROPATHOLOGICA (2021)
The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration
Anne-Laure Mahul-Mellier et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
GDNF/RETSignaling Pathway Activation Eliminates Lewy Body Pathology in Midbrain Dopamine Neurons
Piotr Chmielarz et al.
MOVEMENT DISORDERS (2020)
Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
Safak Er et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2020)
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020
Kevin McFarthing et al.
JOURNAL OF PARKINSONS DISEASE (2020)
Emerging therapies in Parkinson disease - repurposed drugs and new approaches
Ahmad Elkouzi et al.
NATURE REVIEWS NEUROLOGY (2019)
Alpha-synuclein structure and Parkinson's disease - lessons and emerging principles
Richard M. Meade et al.
MOLECULAR NEURODEGENERATION (2019)
Bromodomains: a new target class for drug development
Andrea G. Cochran et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Structures of fibrils formed by α-synuclein hereditary disease mutant H50Q reveal new polymorphs
David R. Boyer et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2019)
Two new polymorphic structures of human full-length alpha-synuclein fibrils solved by cryo-electron microscopy
Ricardo Guerrero-Ferreira et al.
ELIFE (2019)
Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease
Carroll Rutherford Fields et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2019)
Exploring the role of post-translational modifications in regulating -synuclein interactions by studying the effects of phosphorylation on nanobody binding
Farah El Turk et al.
PROTEIN SCIENCE (2018)
Cryo-EM structure of alpha-synuclein fibrils
Ricardo Guerrero-Ferreira et al.
ELIFE (2018)
Amyloid fibril structure of α-synuclein determined by cryoelectron microscopy
Yaowang Li et al.
CELL RESEARCH (2018)
Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons
Jordi Pujols et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Cryo-EM of full-length α-synuclein reveals fibril polymorphs with a common structural kernel
Binsen Li et al.
NATURE COMMUNICATIONS (2018)
The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease
Diana L. Price et al.
SCIENTIFIC REPORTS (2018)
Species and cell-type properties of classically defined human and rodent neurons and glia
Xiao Xu et al.
ELIFE (2018)
GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP)
F. Anthony Romero et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
Loren M. Lasko et al.
NATURE (2017)
Precision medicine for disease modification in Parkinson disease
Alberto J. Espay et al.
NATURE REVIEWS NEUROLOGY (2017)
Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease
Lena F. Burbulla et al.
SCIENCE (2017)
Parkinson disease
Werner Poewe et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
CBP/p300 Bromodomains Regulate Amyloid-like Protein Aggregation upon Aberrant Lysine Acetylation
Heidi Olzscha et al.
CELL CHEMICAL BIOLOGY (2017)
Molecular Diversity of Midbrain Development in Mouse, Human, and Stem Cells
Gioele La Manno et al.
CELL (2016)
Structural disorder of monomeric α-synuclein persists in mammalian cells
Francois-Xavier Theillet et al.
NATURE (2016)
CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses
Ariane Hammitzsch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease
Jens Wagner et al.
ACTA NEUROPATHOLOGICA (2013)
The Genetics of Parkinson's Disease: Progress and Therapeutic Implications
Andrew B. Singleton et al.
MOVEMENT DISORDERS (2013)
100 years of Lewy pathology
Michel Goedert et al.
NATURE REVIEWS NEUROLOGY (2013)
Medium-throughput computer aided micro-island method to assay embryonic dopaminergic neuron cultures in vitro
A. Planken et al.
JOURNAL OF NEUROSCIENCE METHODS (2010)
Missing pieces in the Parkinson's disease puzzle
Jose A. Obeso et al.
NATURE MEDICINE (2010)
Cell systems and the toxic mechanism(s) of alpha-synuclein
Mark R. Cookson et al.
EXPERIMENTAL NEUROLOGY (2008)
Share Paper
